Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

42.59USD
1 Aug 2013
Price Change (% chg)

$2.07 (+5.11%)
Prev Close
$40.52
Open
$40.25
Day's High
$42.80
Day's Low
$39.78
Volume
380,179
Avg. Vol
319,835
52-wk High
$42.80
52-wk Low
$21.06

SGEN.OQ

Chart for SGEN.OQ

About

Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin... (more)

Overall

Beta: 1.12
Market Cap (Mil.): $5,164.10
Shares Outstanding (Mil.): 121.27
Dividend: --
Yield (%): --

Financials

  SGEN.OQ Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -0.40 -- --
ROI: -12.60 -2.58 18.76
ROE: -20.81 -2.66 19.59
Search Stocks

BRIEF-Seattle Genetics down 3.6 percent in premarket

NEW YORK, Feb 13 - Seattle Genetics Inc : * Shares down 3.6 percent in premarket trading after results

13 Feb 2013

Competitors

  Price Change
PT Millennium Pharmacon Int. Tbk (SDPC.JK) Rp. 115.00 -4.00
Eisai Co., Ltd (4523.T) ¥4,295 +130.00
Pfizer Inc. (PFE.N) $29.11 -0.12
Novartis AG (NOVN.VX) CHF67.95 +1.35
Merck & Co., Inc. (MRK.N) $48.58 +0.41
Bayer AG (BAYGn.DE) €89.91 +0.48
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.54 -0.31
GlaxoSmithKline plc (GSK.L) 1,722.50p +10.00
Eli Lilly & Co. (LLY.N) $53.50 +0.39

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: S&P Capital IQ Factual Report
$127.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks